Navigation Links
Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock
Date:2/16/2011

MINNEAPOLIS, Feb. 16, 2011 /PRNewswire/ -- Kips Bay Medical, Inc. ("Kips Bay"), a development stage medical device company focused on developing, manufacturing and commercializing external saphenous vein support technology, or eSVS MESH, for use in coronary artery bypass grafting, or CABG, today announced that it has closed its previously announced offering of 2,062,500 shares of its common stock at a price of $8.00 per share.  

Kips Bay received aggregate net proceeds of approximately $13.6 million after deducting underwriting discounts and commissions and offering expenses payable by Kips Bay. Kips Bay expects to use the net proceeds of this offering to seek regulatory approval to market eSVS MESH in the United States and abroad, including human clinical trials in the United States; develop and test additional applications of eSVS MESH; make certain milestone payments for acquired intellectual property; and for working capital and general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering, and Newbridge Securities Corporation, Caris & Company and Chardan Capital Markets, LLC acted as co-managers.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting the U.S. Securities and Exchange Commission website at http://www.sec.gov. Alternatively, a copy of the prospectus related to this offering may be obtained from Rodman & Renshaw, LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NY, 10020, telephone: 212-430-1710 or email: prospectus@rodm.com.

About Kips Bay Medical, Inc:  Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a development stage medical device company focused on developing, manufacturing and commercializing its eSVS MESH for use in coronary artery bypass grafting surgery.  Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com.For further information, please contact:Kips Bay Medical, Inc.Manny Villafana, Chairman and Chief Executive OfficerScott Kellen, Chief Financial OfficerPhone: +1-763-235-3540Email: manny.villafana@kipsbaymedical.com
'/>"/>

SOURCE Kips Bay Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... SPRING, Md. , March 28, 2017 /PRNewswire-USNewswire/ ... approved Dupixent (dupilumab) injection to treat adults with ... patients whose eczema is not controlled adequately by ... are not advisable. Dupixent can be used with ... of Dupixent demonstrates our commitment to approving new ...
(Date:3/28/2017)... LONDON , March 28, 2017  "US ... insight on the various indicators and trend analysis ... generics drugs in mainstream pharmaceutical market in US. ... responsible for the growth on cancer generics drugs ... resulted in saving of billions of dollars for ...
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, Allergy ... released a new white paper to underscore the ... latex in healthcare. Specifically, there is substantial confusion as to ... FDA has urged manufacturers to drop the term "latex free" ... of the challenge to ensure a product is completely devoid ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is ... to take the Diabetes Risk Test to find out if they are at risk ... Airports will light up the evening sky by programming the LAX pylons the color ...
(Date:3/28/2017)... YORK (PRWEB) , ... March 28, 2017 , ... ... NTX Technology™, is the first technology to directly address the resolution to globally ... NTX Technology™ is a patented compound of FDA and TTB approved ingredients that ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is ... Pharm.D., FASCP. The program was recently launched on March 1, and Dr. Wentz ... function. , Dr. Izabella Wentz is a licensed pharmacist and a foremost ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
Breaking Medicine News(10 mins):